Financials in USD. Standardized financial statements.
A compact view of how Reata Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.22M | $11.49M | $9.02M | $26.52M | $53.59M | $48.06M | $49.86M | $50.32M | $51.95M | $51.20M |
| Revenue Growth? | -80.7% | +27.4% | -66.0% | -50.5% | +11.5% | -3.6% | -0.9% | -3.1% | +1.5% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $124.40M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $2.22M | $11.49M | $9.02M | -$97.88M | $53.59M | $48.06M | $49.86M | $50.32M | $51.95M | $51.20M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | -369.1% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $280.25M | $256.20M | $235.34M | $187.34M | $130.47M | $94.97M | $56.74M | $50.65M | $48.33M | $61.58M |
| Operating Income? | -$270.15M | -$244.71M | -$226.32M | -$285.22M | -$76.88M | -$46.91M | -$7.10M | -$366,000 | $3.58M | -$10.42M |
| EBITDA? | -$269.02M | -$243.50M | -$232.32M | -$278.03M | -$73.91M | -$46.48M | -$6.41M | $1.45M | $6.09M | -$7.49M |
| Income Before Tax | -$311.93M | -$297.84M | -$270.24M | -$290.16M | -$80.52M | -$47.67M | -$6.67M | -$302,000 | $3.67M | -$10.35M |
| Income Tax Expense | -$25,000 | -$450,000 | -$22.49M | $8,000 | $26,000 | $3,000 | -$441,000 | $1.15M | $2.98M | $24.76M |
| Net Income? | -$311.90M | -$297.39M | -$247.75M | -$290.17M | -$80.55M | -$47.67M | -$6.23M | -$1.45M | $689,000 | -$35.10M |
| EPS? | $-8.59 | $-8.19 | $-7.35 | $-9.54 | $-2.91 | $-1.99 | $-0.31 | $-0.26 | $0.13 | $-6.38 |
| Diluted EPS? | $-8.59 | $-8.19 | $-7.35 | $-9.54 | $-2.91 | $-1.99 | $-0.31 | $-0.07 | $0.03 | $-1.76 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality